Microbot Medical Appoints Aileen Stockburger to the Board of Directors
01 April 2020 - 10:00PM
Microbot Medical Inc. (Nasdaq: MBOT) announced the appointment of
Aileen Stockburger to the Company's Board of Directors, effective
April 1, 2020. Ms. Stockburger is an experienced executive and
consultant with extensive expertise in strategizing, managing and
closing sizable, complex worldwide mergers and acquisitions,
licensing agreements and divestitures, as well as expertise in
business development, strategic planning and finance.
“We are excited to have Aileen join us and
strengthen our leadership team’s core capabilities, as her
strategic track record and vast industry network will add
tremendous value to the organization”, commented Harel Gadot, CEO,
President and Chairman. “Her proven experience in merger and
acquisition transactions as well as the formation and execution of
strategic collaborations across the industry, will greatly enhance
the Company’s ability to achieve its strategic growth
objectives.”
During her almost 30 years at Johnson &
Johnson, Ms. Stockburger held several business development and
finance roles in Medical Devices, Corporate and Consumer. She
served as Worldwide Vice President of Business Development for the
DePuy Synthes Group of Johnson & Johnson, where she oversaw the
group’s merger and acquisition activities. While in that role, she
played leading and significant roles in over $70 billion worth of
transactions, including: Johnson and Johnson’s acquisition of
Synthes, as well as Pfizer Consumer HealthCare, Aveeno, BabyCenter,
OraPharma, DePuy, DePuy Mitek, Kodak Clinical Diagnostics and
Neutrogena. Before joining Johnson & Johnson, Aileen spent
three years at PriceWaterhouse Coopers, where she earned her CPA
certification. She received her BS and MBA from the Wharton School,
University of Pennsylvania.
“Throughout my career I have sought out
opportunities that allow me to use my specific skills to help
effect meaningful change and impact to the healthcare market,”
commented Ms. Stockburger. “I have watched Microbot Medical
the past few years, albeit from a distance, and my enthusiasm to
join the Board at this specific time is due to its progress
developing highly advanced and revolutionary robotic systems that
will transform the future of healthcare. I believe that my
expertise, combined with Microbot’s assets and ambition, will allow
us to address new and emerging growth markets.”
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a
pre-clinical medical device company that specializes in
transformational micro-robotic technologies, focused primarily on
both natural and artificial lumens within the human body.
Microbot’s current proprietary technological platforms provide the
foundation for the development of a Multi Generation Pipeline
Portfolio (MGPP).
Microbot Medical was founded in 2010 by Harel
Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of
improving clinical outcomes for patients and increasing
accessibility through the use of micro-robotic technologies.
Further information about Microbot Medical is available at
http://www.microbotmedical.com.
Safe Harbor
Statements pertaining to the registered direct
offering, timing, the amount and anticipated use of proceeds and
statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for Microbot Medical Inc. and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management, constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 and
the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words
such as “will,” “believes,” “plans,” “anticipates,” “expects” and
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions and
the satisfaction of customary closing conditions, risks inherent in
the development and/or commercialization of potential products,
including LIBERTY, the outcome of its studies to evaluate the SCS
and other existing and future technologies, uncertainty in the
results of pre-clinical and clinical trials or regulatory pathways
and regulatory approvals, uncertainty resulting from the COVID-19
pandemic, need and ability to obtain future capital, and
maintenance of intellectual property rights. Additional information
on risks facing Microbot Medical can be found under the heading
“Risk Factors” in Microbot Medical’s periodic reports filed with
the Securities and Exchange Commission (SEC) and in the prospectus
supplement related to the registered direct offering to be filed
with the SEC, which are or will be available on the SEC’s web site
at www.sec.gov. Microbot Medical disclaims any intent or obligation
to update these forward-looking statements, except as required by
law.
Investor Contact:
Michael PolyviouEVC
Groupmpolyviou@evcgroup.com732-933-2754
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Apr 2024 to May 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From May 2023 to May 2024